170787-99-2 | Efaproxiral sodium

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$15.00	$10.00
10mg	99%	in stock	$19.00	$13.00
50mg	99%	in stock	$40.00	$28.00
100mg	99%	in stock	$63.00	$44.00
250mg	99%	in stock	$103.00	$72.00
1g	99%	in stock	$275.00	$192.00
5g	99%	in stock	$963.00	$674.00

Description

• Catalog Number: AE81469
• Chemical Name: Efaproxiral sodium
• CAS Number: 170787-99-2
• Molecular Formula: C20H22NNaO4
• Molecular Weight: 363.38275000000004
• MDL Number: MFCD02093864
• SMILES: O=C(Nc1cc(C)cc(c1)C)Cc1ccc(cc1)OC(C(=O)[O-])(C)C.[Na+]

Computed Properties

• Complexity: 464
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 26
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6

Literature

• Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure.

  Journal of the American College of Cardiology 20080826

• Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral.

  Chemical communications (Cambridge, England) 20080307

• Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.

  American journal of clinical oncology 20071201

• The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice.

  Radiation research 20070801

• Using exposure-response and biomarkers to streamline early drug development.

  Ernst Schering Research Foundation workshop 20070101

• Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.

  British journal of cancer 20060619

• Role of efaproxiral in metastatic brain tumors.

  Expert review of anticancer therapy 20060401

• Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.

  International journal of radiation oncology, biology, physics 20060315

• Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry.

  Journal of mass spectrometry : JMS 20060301

• Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors.

  Experimental biology and medicine (Maywood, N.J.) 20060301

• Radiation sensitization with redox modulators: a promising approach.

  International journal of radiation oncology, biology, physics 20060201

• New hope for old drug in patients with brain metastases.

  The Lancet. Oncology 20060201

• Efaproxiral: should we hold our breath?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060101

• Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.

  The Annals of pharmacotherapy 20051201

• Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050901

• Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study.

  International journal of radiation oncology, biology, physics 20050401

• Hit to Lead Success Stories--IBC Conference: Effective chemistry strategies for reducing attrition rates and speeding lead compounds into the pipeline. 31 January-1 February 2005, San Diego, CA, USA.

  IDrugs : the investigational drugs journal 20050301

• R-state hemoglobin bound to heterotropic effectors: models of the DPG, IHP and RSR13 binding sites.

  FEBS letters 20050131

• Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.

  Drugs in R&D 20050101

• Effects of a pharmacologically-induced shift of hemoglobin-oxygen dissociation on myocardial energetics during ischemia in patients with coronary artery disease.

  Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 20050101

• Modeling of the response of ptO2 in rat brain to changes in physiological parameters.

  Advances in experimental medicine and biology 20050101

• Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.

  International journal of radiation oncology, biology, physics 20040701

• Efaproxiral: a novel radiation sensitiser.

  Expert opinion on investigational drugs 20040501

• Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.

  Cancer chemotherapy and pharmacology 20040101

• Efaproxiral (Allos Therapeutics).

  IDrugs : the investigational drugs journal 20030801

• RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030615

• Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy.

  Advances in experimental medicine and biology 20030101

• The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats.

  Advances in experimental medicine and biology 20030101

• The effect of RSR13, a synthetic allosteric modifier of hemoglobin, on brain tissue pO2 (measured by EPR oximetry) following severe hemorrhagic shock in rats.

  Advances in experimental medicine and biology 20030101

• [Blood doping and cardiovascular consequences].

  Presse medicale (Paris, France : 1983) 20021221

• Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020715

• Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.

  American journal of physiology. Heart and circulatory physiology 20020701

• Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.

  American journal of physiology. Heart and circulatory physiology 20020501

• Effects of enhanced oxygen release from hemoglobin by RSR13 in an acute renal failure model.

  Kidney international 20011001

• Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13.

  Radiation research 20010901

• High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector.

  Protein science : a publication of the Protein Society 20010501

• A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.

  International journal of radiation oncology, biology, physics 20010315

• Allosteric modification of oxygen delivery by hemoglobin.

  Anesthesia and analgesia 20010301

• RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20010101